News

Rotigotine Patch has been developed as a treatment for Parkinson’s disease and restless legs syndrome. The patch will provide a continuous release of the drug substance and maintains

Under the agreement Mitsubishi is responsible for any necessary development and regulatory approval costs, pay undisclosed upfront, pre-commercial milestones and pay Nuron significant royalties on commercial sales in

Sycrest is a sublingual tablet marketed as Sycrest in Europe, and as Saphris in other markets worldwide. Sycrest is an antipsychotic that differs structurally from currently available medications

Iferanserin is a new chemical entity (NCE), that acts by targeting a specific serotonin receptor (5HT2A) for the topical treatment of hemorrhoids. The Phase 2b trial is a

Priority Review for Cinryze was granted for all three requested indications, prevention, pre-procedure prevention, and acute treatment of attacks of Hereditary Angioedema (HAE). Priority Review will allow for

According to the company, the ability to fund both the Type 1 diabetes and GVHD human clinical trials are subject to the company raising additional capital in the

The drug candidate is currently in clinical phase II under the EU financed NEMO (Treatment of NEonatal seizures with Medication Off-patent project). Under the collaboration, O4CP will be

Krill oil is known to deliver high amounts of omega-3 without the risk of mercury and lead contamination as is the case with fish oil. The phospholipid structure

The Navy Medicine Research contract is a five-year, indefinite delivery, indefinite quantity, multiple-award contract with a total potential value of $497m to all awardees if all options are